- Patients must meet the ACR criteria for fibromyalgia (ie, widespread pain present for
at least 3 months, and pain in at least 11 of 18 specific tender point sites.
- Patients must complete the double-blind study.
- Patients who experienced a serious adverse event during the previous fibromyalgia
study, which was determined to be related to the study medication.